SecBot SecBot
8-K ·Filed Jul 30, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000872589-26-000023
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The full repayment of the Sanofi Development Balance removes a drag on collaboration profits starting Q3, providing a structural tailwind to earnings. With double-digit top- and bottom-line growth, raised gross margin guidance, and a $2.5B buyback authorization, the stock should re-rate higher. Key catalysts to watch: cemdisiran PDUFA in November 2026 and Dupixent CSU expansion in pediatrics.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

REGN drug pipeline →

Otarmeni

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already FDA-approved (April 23, 2026); commercially available in the U.S.
Next catalyst
BLA filing · 2026

What to watchOtarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.

Price Chart

Loading chart...

Executive Summary

Regeneron reported Q2 2026 revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, driven by Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%). Guidance was modestly tightened higher on R&D and gross margins, and the Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3. The strong beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.

Key Financial Metrics

EPS
$14.29
est $10.20 · +40.1%
Revenue
$4.3B
est $3.8B · +12.0% · +16.7% YoY
Rating
strong beat
Free Cash Flow
$1.4B
Gross Margin
78%

Key Facts

  • Total revenues $4.29B, +17% YoY vs $3.68B
  • Non-GAAP EPS $14.29, +11% YoY, 40.1% above $10.20 consensus
  • Dupixent global net sales $6.0B, +38% YoY (record)
  • EYLEA HD U.S. net sales $596M, +52% YoY (record)
  • Libtayo global net sales $489M, +30% YoY (record)
  • Sanofi collaboration revenue $2.17B, +51% YoY; Development Balance fully repaid
  • GAAP net income $1.30B, -7% YoY due to $127M IPR&D charge and higher tax rate
  • 2026 guidance: GAAP R&D narrowed to $6.50-6.635B; non-GAAP gross margin raised to 84-85%
  • Share repurchases of $1.2B in Q2, $2.0B YTD; $2.5B remaining
  • Cemdisiran NDA accepted for priority review in gMG, PDUFA Nov 2026

Financial Impact

Non-GAAP EPS beat consensus by $4.09 (40.1%); revenue beat by $460M (12.0%)

revenueepscollaboration revenuegross marginshare repurchases

Risk Factors

  • Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
  • EYLEA franchise U.S. sales declined 12% YoY as patients transition to EYLEA HD at lower net price
  • GAAP net income declined 7% YoY due to $127M IPR&D charge and higher effective tax rate (15.1% vs 8.4%)
  • Patent litigation related to EYLEA remains an overhang

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000872589-26-000023
Document: 0000872589-26-000023-index-headers.html0000872589-26-000023
Document: 0000872589-26-000023-index.html0000872589-26-000023
Document: 0000872589-26-000023.txt0000872589-26-000023
8-K Data (Synthetic)0000872589-26-000023

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026